Results 171 to 180 of about 515,448 (335)

Corticosteroids as adjunctive therapy in patients with acute/subacute paracoccidioidomycosis presenting a severe paradoxical inflammatory reaction: Two case reports and literature review. [PDF]

Braz J Infect Dis
Stringelli-Brandão P, Fuga MP, Sguassábia MK, Rocha IH, Silva-Vergara ML.   +4 more
europepmc   +1 more source

SAFETY AND EFFICACY OF A LOW DOSE CORTICOSTEROID REGIMEN FOR THE INDUCTION TREATMENT OF LUPUS NEPHRITIS - CYCLONES TRIAL: CYCLOPHOSPHAMIDE LOW DOSE AND NO EXTRA STEROID

, 2021
Michelle Lopes, Sandra Gofinet Pasoto, Emily Figueiredo Neves Yuki, Lorena Elizabeth Betancourt Villamarín, Francisco Fellipe Claudino Formiga, Débora Cordeiro do Rosário, L.M.K.R. Brandão, Carolina Torres Ribeiro, Tatiana do Nascimento Pedrosa, Alex Cardoso Lopes, Eduardo Ferreira Borba, Luciana Parente Costa Seguro, Nádia Emi Aikawa, Eloísa Bonfá   +13 more
openalex   +1 more source

Steroid-sparing strategies for managing immune-related adverse events. [PDF]

J Immunother Cancer
Huang JJ, YousefiAsl M, Singh N, Grivas P, Bhatia S.   +4 more
europepmc   +1 more source

Dyspnea and Inhaled Corticosteroid and Long-acting β-Agonist Therapy in an Occupational Cohort: A Longitudinal Study

, 2020
Barbara Putman, Lies Lahousse, Ankura Singh, Rachel Zeig‐Owens, Charles B. Hall, Melissa Fazzari, Theresa Schwartz, Mayris P. Webber, Hillel W. Cohen, David J. Prezant, Michael D. Weiden   +10 more
openalex   +2 more sources

P1603Efficacy of combination therapy of methotrexate and low-dose corticosteroid for cardiac sarcoidosis evaluated by fuluorine-18 fluorodeoxyglucose positron emission tomography [PDF]

, 2018
Takafumi Yokomatsu, S. Hojo, Tetsuma Kawaji, Akihiro Kushiyama, Kenji Nakatsuma, Kazuhisa Kaneda, Masashi Kato, S Miki   +7 more
openalex   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Managing Acute Severe Ulcerative Colitis in 2025 and Beyond. [PDF]

Curr Gastroenterol Rep
Goyal MK, Hassan SA, Berinstein JA.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Corticosteroids and hospital-acquired pneumonia. [PDF]

Pneumonia (Nathan)
Pasqua LA, Cilloniz C, Torres A.
europepmc   +1 more source

Predictive Parameters of Dropout During Inhaled Corticosteroid Tapering [PDF]

, 2002
Daniel K.C. Lee, Graeme P. Currie, Brian J. Lipworth   +2 more
openalex   +1 more source